Table 2.
Typbar Typhoid Conjugate Vaccine Evaluation in Field Settings to Inform Country-Level Decision-Making: Reactogenicity, Immunogenicity, and Coadministration Studies
| Country | Design | Control Vaccine | Age | Study Period | No. Enrolled | Coadministered Vaccines | Other |
|---|---|---|---|---|---|---|---|
| Burkina Faso | Individually randomized | Inactivated poliovirus | 9–11 mo | Nov 2018–Aug 2019 | 100 | Measles, rubella, yellow fever | … |
| Burkina Faso | Individually randomized | Inactivated poliovirus | 15–23 mo | Nov 2018–Aug 2019 | 150 | Meningococcal serogroup A conjugate, measles, rubellaa | … |
| Nepal | Individually randomized | Meningococcal serogroup A conjugate | 9–12 mo | Nov 2017–ongoingb | 100 | 1 vs 2 doses | |
| Malawi | Individually randomized | Meningococcal serogroup A conjugate | 9 mo | Mar 2021–ongoingb | 100 | Measles, rubella | HIV-exposed, 1 vs 2 doses |
aMeasles rubella second dose coadministered; no assessment of immunogenicity.
bInterrupted by COVID-19 pandemic.